Viewing Study NCT05188859


Ignite Creation Date: 2025-12-24 @ 2:50 PM
Ignite Modification Date: 2026-02-02 @ 3:04 AM
Study NCT ID: NCT05188859
Status: RECRUITING
Last Update Posted: 2025-05-31
First Post: 2021-12-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Mesothelioma, Malignant View
None Mesothelioma, Malignant Pleural View
None Mesothelioma Malignant Advanced View
Keywords: